S-11a2234415zs-1.htmS-1Use these links to rapidly review the documentTABLE OF CONTENTSTable of ContentsAs filed with the Securities and Exchange Commission on February 20, 2018Registration No. 333-UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933Dova Pharmaceuticals, Inc.(Exact name of registrant as specified in its charter)Delaware(State or other jurisdiction ofincorporation or organization)2834(Primary Standard IndustrialClassification Code Number)81-3858961(I.R.S. EmployerIdentification Number)240 Leigh Farm Road, Suite 245Durham, North Carolina 27707(919) 748-5975(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)Alex SapirPresident and Chief Executive OfficerDova Pharmaceuticals, Inc.240 Leigh Farm RoadSuite 245Durham, NC 27707(919) 748-5975(Name, address, including zip code, and telephone number, including area code, of agent for service)Copies to:Divakar GuptaDarren DeStefanoMark BallantyneCooley LLP1114 Avenue of the AmericasNew York, New York 10036(212) 479-6000Deanna KirkpatrickDavis Polk & Wardwell LLP450 Lexington AvenueNew York, New York 10017(212) 450-4000Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective date of this registration statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
are an "emerging growth company" as defined under the federal securities laws and will be subject to reduced public company reporting requirements.​​​​​​​​Per shareTotal​​​​​​​​Public offering price$$Underwriting discounts and commissions(1)$$Proceeds to Dova Pharmaceuticals, Inc., before expenses$$​​​​​​​​(1)    We have also agreed to reimburse the underwriters for certain FINRA-related expenses.
about                           , 2018.J.P. MorganJefferiesEvercore ISIProspectus dated                           , 2018Table of ContentsTable of contentsPageProspectus summary1Risk factors13Special note regarding forward-looking statements15Industry and other data16Use of proceeds17Dividend policy18Capitalization19Dilution20Selected financial data22Certain relationships and related party transactions23Principal stockholders27Description of capital stock29Shares eligible for future sale35Material U.S. federal income tax consequences to non-U.S. holders37Underwriting41Legal matters49Experts49Incorporation of certain information by reference50Neither we nor the underwriters have authorized anyone to provide you with information other than that contained or incorporated by reference in this prospectus or any free
indication that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.8Table of ContentsThe offeringCommon stock offered by us2,500,000 sharesCommon stock to be outstanding immediately after this offering28,152,457 sharesOption to purchase additional sharesWe have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase a maximum of 375,000 additional shares of common stock.Use of proceedsWe estimate that the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be
$80.9 million, or $93.1 million if the underwriters exercise their option to purchase additional shares in full, based on an assumed public offering price of $34.68 per share, the last reported sales price of our common stock on The NASDAQ
assumes:•no exercise of outstanding options outstanding as of December 31, 2017; and•no exercise of the underwriters' option to purchase additional shares of common stock.10Table of ContentsSummary consolidated financial dataThe following tables set forth, for the periods and as of the dates indicated, our summary financial data.
addition, we have filed a registration statement on Form S-8 registering the issuance of approximately 6.0 million shares of common stock subject to options or other equity awards
financial statements and the related notes incorporated by reference in this prospectus.​​​​​​​​As ofDecember 31, 2017ActualAs adjusted​​​​​​​​(in thousands, exceptshare and per share data)Cash and cash equivalents$94,846$175,744​​​​​​​​Note payable, short-term30,21230,212Stockholders' equity:Common stock, $0.001 par value; 100,000,000 shares authorized and 25,652,457 shares issued and outstanding, actual; 100,000,000 shares authorized and
Securities LLC and Jefferies LLC for a period of 90 days after the date of this prospectus.Registration rightsUpon the closing of this offering, the holders of approximately 21 million shares of our common stock will be entitled to specified
offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:​​​​​NameNumber ofshares​​​​​J.P. Morgan Securities LLCJefferies LLCEvercore Group L.L.C.​​​​​Total​​​​​The
The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.Where you can find additional informationWe have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of common stock
further information with respect to our company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits.